BioSpace News Archive

Policy

FDA 510(k) Clearance Expands Labelling of MolecuLight i:X® to Include the Ability to Identify Regions Containing Elevated Load and More Bacterial Species

MolecuLight Inc.announces that it has received an expansion to its FDA 510 clearance for the MolecuLight i:X® imaging device’s ability to detect the location of elevated bacterial loads in wounds.

June 29, 2022
·
4 min read
Business

Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28

Merck, known as MSD outside the United States and Canada, will hold its second-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, July 28.

June 29, 2022
·
3 min read
Business

Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets

Generian Pharmaceuticals, Inc. (“Generian”) and Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma Inc. ) announced today that they have entered into a collaboration and exclusive license agreement to discover and develop novel small molecules for undruggable therapeutic targets by using a proprietary drug discovery platform for diseases that have limited treatment options.

June 29, 2022
·
4 min read
Drug Development

Positive data from the clinical phase I MAD study with AlzeCure’s Alzheimer’s project NeuroRestore ACD856

AlzeCure Pharma AB today announced that the company has completed the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, with a focus on Alzheimer’s disease.

June 29, 2022
·
6 min read
Drug Development

MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial

Molecular Targeting Technologies, Inc. (MTTI), announced that the first patient has been dosed in a clinical trial of EBTATE ( 177 Lu-DOTA-EB-TATE) for the treatment of patients with advanced, well differentiated neuroendocrine tumors.

June 29, 2022
·
1 min read
Genetown

Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile

STX-721 is a next-generation, highly selective Exon 20 mutant EGFR inhibitor designed for a best-in-class profile to overcome efficacy and toxicity limitations of currently available agents.

June 29, 2022
·
3 min read
btt Corp. Raises $29.3 Million to Deploy Diagnostic and Treatment Technologies Based on Brain Thermodynamics and Thermoregulatory Frequencies

btt Corp. (btt), a medical technology company focused on the development of innovative devices and treatments for targeted heat shock protein induction, today announced that Oklahoma Rock Holdings, LLC (Oklahoma Rock) has completed an investment of $29.3 million.

June 29, 2022
·
4 min read
Business

Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger’s Novel Early Cancer Detection Platform

Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection.

June 29, 2022
·
3 min read
Pharm Country

Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development.

June 29, 2022
·
5 min read
Business

Hemodialysis Technology Company Diality Joins Innovative Kidney Care Campaign, Seeks to Improve Choice for Kidney Patients

Hemodialysis Technology Company Diality Joins Innovative Kidney Care Campaign, Seeks to Improve Choice for Kidney Patients.

June 29, 2022
·
2 min read